#ONC-841
LightNews LightNews
newsen.bsky.social
OncoC4 Initiates First Phase 1/2 Clinical Trial for Alzheimer's Disease Therapy ONC-841#USA#Rockville#Alzheimer's#OncoC4#ONC-841
OncoC4 Initiates First Phase 1/2 Clinical Trial for Alzheimer's Disease Therapy ONC-841
OncoC4 Inc. has started dosing the first participant in its Phase 1/2 trial of ONC-841, an innovative Alzheimer’s treatment, after regulatory approval.
third-news.com
April 9, 2026 at 11:20 AM
l2plabs.bsky.social
OncoC4 announces first participant's dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer's disease
ROCKVILLE, Md., April 9, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical stage biopharmaceutical company, today announced first participant's dosing following the clearance of the Investigational New Drug (IND) application for a Phase 1/2 clinical trial of ONC-841, the company's...
dlvr.it
April 9, 2026 at 11:01 AM